Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Ionis Pharmaceuticals. The associated price target remains the same with $95.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Ionis Pharmaceuticals’ strategic positioning and growth potential. The recent EU approval of Olezarsen, branded as TRYNGOLZA, for familial chylomicronemia syndrome (FCS) is a significant milestone. This approval not only validates the company’s strategy but also serves as a stepping stone to the larger severe hypertriglyceridemia (sHTG) market, which is expected to drive substantial commercial success.
Additionally, the promising results from the CORE/CORE2 studies demonstrate Olezarsen’s efficacy in reducing triglyceride levels and acute pancreatitis events in sHTG patients, reinforcing its potential as a groundbreaking therapy. The anticipated U.S. launch in the second half of 2026 further supports the Buy rating, with regulatory momentum and a rich pipeline of upcoming catalysts, including key presentations and updates, bolstering investor confidence. The valuation, based on a discounted cash flow analysis, suggests a 12-month price target of $95 per share, reflecting the company’s robust prospects and potential upside from its diverse product portfolio.
In another report released on September 15, Leerink Partners also maintained a Buy rating on the stock with a $63.00 price target.